Proper application of anticoagulation therapy on cancer-associated venous thrombosis

Ho-Young Yhim

doi:10.1007/s44313-024-00029-3

Quick links

Most Cited Most Read Ahead of Print Archives Go to E-submission

REVIEW

Split Viewer

Blood Res (2024) 59:25

Published online August 2, 2024

https://doi.org/10.1007/s44313-024-00029-3

Proper application of anticoagulation therapy on cancer-associated venous thrombosis

Ho‑Young Yhim1*

Author Info. +

¹ Department of Internal Medicine, Jeonbuk National University Medical School, 20 Geonji‑Ro, Deokjin‑Gu, Jeonju 54907, Republic of Korea

Correspondence to : *Correspondence:
Ho‑Young Yhim
yhimhy@jbnu.ac.kr

Received: May 29, 2024; Accepted: July 25, 2024

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Abstract

Go to

Abstract

Cancer-associated venous thromboembolism (VTE) significantly impacts morbidity and mortality. The introduction of direct oral anticoagulants over the past decade has revolutionized VTE treatment in patients with active cancer, offering potential advantages over traditional therapies. However, uncertainties persist regarding the optimal selection and dosage of anticoagulants, particularly in patients with specific risk factors for bleeding, such as certain cancer types (e.g., upper gastrointestinal cancer, genitourinary cancer, primary or metastatic brain tumor, and hematologic malignancies) and specific patient characteristics (e.g., renal dysfunction and thrombocytopenia). Recent data on the thrombotic risk associated with low thrombotic burden VTE, such as subsegmental pulmonary embolism and isolated distal deep vein thrombosis, underscore the need for updated management strategies in daily clinical practice. This review aims to explore these issues and highlight the evolving landscape of cancer-associated VTE management.

Keywords Anticoagulation, Cancer, Venous thromboembolism